Tag: half

Contractors facing credit challenges in 2025 are fueling record demand for alternative financing, as ROK Financial expands business loan programs designed to keep projects funded and crews working nationwide.

NEW YORK, Aug. 16, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Novo Nordisk A/S (NYSE:NVO), Altimmune, Inc. (NASDAQ:ALT), SelectQuote, Inc. (NYSE:SLQT) and Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.

SINGAPORE, Aug. 15, 2025 (GLOBE NEWSWIRE) -- Ebang International Holdings Inc. (Nasdaq: EBON, the “Company,” “we,” “us” or “our”), today announced its unaudited financial results for the first six months of fiscal year 2025.

NESS ZIONA, Israel, Aug. 15, 2025 (GLOBE NEWSWIRE) -- Foresight Autonomous Holdings Ltd. (Nasdaq and TASE: FRSX) (“Foresight” or the “Company”), an innovator in 3D perception systems, today reported financial results for the second quarter and first half of 2025.

BOSTON, Aug. 15, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that, effective on August 12, 2025, the company issued inducement awards to Adam Craig, M.D., John Volpone and David Kirske under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan (the “2019 Inducement Plan”), consisting of (i) options to purchase an aggregate of 4,250,718 shares of X4’s common stock granted to Dr. Craig, (ii) options to purchase an aggregate of 4,250,718 shares of X4’s common stock granted to Mr. Volpone and (iii) options to purchase an aggregate of 2,833,812 shares of X4’s common stock granted to Mr. Kirske. In addition, effective on August 14, 2025, the company issued additional inducement awards to Dr. Craig, Mr. Volpone and Mr. Kirske under the 2019 Inducement Plan, consisting of (i) options to purchase an aggregate of 529,201 shares of X4’s common stock granted to Dr. Craig, (ii) options to purchase an aggregate of 529,201 shares of X4’s common stock granted to Mr. Volpone and (iii) options to purchase an aggregate of 352,800 shares of X4’s common stock granted to Mr. Kirske.

Tonmya is the first FDA-approved therapy for the treatment of fibromyalgia in over 15 years